Eversept Partners, LP Collegium Pharmaceutical, Inc Transaction History

Eversept Partners, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 13, 2020	SELL	$13.89 - $25.45 $1.55 Million - $2.83 Million	-111,361 Closed	0 $0
Q4 2019 Nov 08, 2023	SELL	$10.7 - $22.24 $523,593 - $1.09 Million	-48,934 Reduced 30.53%	111,361 $2.29 Million
Q4 2019 Feb 13, 2020	SELL	$10.7 - $22.24 $523,593 - $1.09 Million	-48,934 Reduced 30.53%	111,361 $2.29 Million
Q3 2019 Nov 08, 2023	BUY	$10.16 - $13.28 $196,037 - $256,237	19,295 Added 13.68%	160,295 $1.84 Million
Q3 2019 Nov 13, 2019	BUY	$10.16 - $13.28 $196,037 - $256,237	19,295 Added 13.68%	160,295 $1.84 Million
Q2 2019 Nov 08, 2023	BUY	$10.62 - $16.59 $1.5 Million - $2.34 Million	141,000 New	141,000 $1.85 Million
Q2 2019 Aug 13, 2019	BUY	$10.62 - $16.59 $1.5 Million - $2.34 Million	141,000 New	141,000 $1.85 Million

247

37.6M

100K

10K

Ticker COLL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 34,126,200
Market Cap $1.06B
Description
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

Stay updated on Eversept Partners, LP with notifications on news.